Disclosure Notice - Major shareholding notification

Press release: Uppsala, July 17, 2020. Dicot AB (publ) ("Dicot" or the "Company") announces today, July 17, the following disclosure notice as a result of the Company's completed rights issue.

Jarl Wikberg, founder, major shareholder and board member of the Company, has reduced his shareholding below the limit of 15 percent. Total shareholding after the transaction, which has taken place via Spotlight Stock Market, amounts to 4,071,770 shares, corresponding to 10.6 percent of the shares and votes in the Company.

Bengt Walfridson has reduced his shareholding below the limit of 5 percent. Total shareholding after the transaction, which has taken place via Spotlight Stock Market, amounts to 1,500,000 shares, corresponding to 3.9 percent of the shares and votes in the Company.

Both changes in shareholdings are attributable to the rights issue carried out by the Company during June 2020.

For further information, please contact:
Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09
E-mail: [email protected]

About Dicot AB                                                                

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 1,600 shareholders. For more information see www.dicot.se.

Ny studie: LIB-01 antas vara nästa generations potensläkemedel

Uppsala, 15 november 2022. Dicots senaste studie av verkningsmekanismen hos LIB-01, dvs hur läkemedlet fungerar i kroppen för att nå önskad effekt, visar att den skiljer sig från dagens potensläkemedel. Detta innebär att LIB-01 kan antas representera en ny generation av potensläkemedel.


New study: LIB-01 assumed to be the next generation of potency drugs

Uppsala, November 15, 2022. Dicot's latest study of the mechanism of action of LIB-01, i.e., how the drug affects the body to achieve the desired effect, shows that it differentiates from today's potency drugs. This means that LIB-01 can be assumed to represent a new generation of potency drugs.


Lyckat första myndighetsmöte för LIB-01

Uppsala, 14 november 2022. Dicot meddelar idag att det första formella myndighetsmötet för LIB-01 inför en ansökan om start av kliniska studier har genomförts. Detta var det första av två planerade vetenskapliga rådgivningsmöten med Läkemedelsverket, i syfte att förankra det underlag som ska ingå i en klinisk prövningsansökan.


Successful first regulatory meeting for LIB-01

Uppsala, November 14, 2022. Dicot announces today that the first regulatory meeting for LIB-01 prior to an application to start clinical trials has been conducted. This was the first of two planned scientific advisory meetings with the Swedish Medical Products Agency, with the purpose of anchoring the scientific background documentation for a clinical trial application.


Valberedningen för Dicot AB utsedd

Pressmeddelande: Uppsala, 3 november 2022. Enligt det beslut om valberedningen som fattades vid årsstämman i Dicot AB den 24 maj 2022 ska valberedningen inför årsstämman den 23 maj 2023 bestå av tre ledamöter representerande de tre största aktieägarna per den sista september 2022.


The Nomination committee for Dicot AB appointed

Press release: Uppsala, November 3, 2022. According to decision at the Annual General Meeting of Dicot AB on May 24, 2022, the Nomination committee for the Annual General Meeting on May 23, 2023, shall consist of three members representing the three largest shareholders as of the end of September 2022.


Rättelse: Dicot AB Delårsrapport januari - september 2022

Pressmeddelande: Uppsala, 1 november 2022. Rättelsen avser att informera om att tidigare pressmeddelande gällande Dicot ABs (publ) delårsrapport för januari - september 2022 ej skulle ha varit markerad med MAR-etikett. 


Correction: Interim Report January-September 2022, Dicot AB

Press release: Uppsala, November 1, 2022. The correction is to inform that the previous press release regarding Dicot AB's (publ) interim report for January - September 2022 should not have been marked with the MAR label.


Dicot AB Delårsrapport januari - september 2022

Pressmeddelande: Uppsala, 1 november 2022. Dicot ABs (publ) delårsrapport för januari - september 2022 finns nu tillgänglig på bolagets hemsida www.dicot.se.


Interim Report January-September 2022, Dicot AB

Press release: Uppsala, November 1, 2022. A summary of the Interim report January - September 2022, for Dicot AB (publ) is now available on the company website www.dicot.se.


Dicot AB (publ) tidigarelägger publicering av finansiell rapport för Q3 2022

Publicering av Dicots rapport för tredje kvartalet kommer tidigareläggas till den 1 november 2022. Tidigare meddelat datum för publicering var den 15 november 2022 


Dicot AB (publ) brings forward publication of financial report for Q3 2022

Publication of Dicot's report for the third quarter will be brought forward to November 1, 2022. Previously announced date for publication was November 15, 2022.


Dicot sänker kostnader genom flytt av tillverkningssteg

Uppsala, 25 oktober 2022. Dicot flyttar delar av tillverkningen av sin läkemedelssubstans för att sänka kostnader och minska transporter. Det är extraktionsprocessen som flyttas till Sydafrika där startmaterialet redan hanteras och där bolaget har etablerade samarbetspartners.


Dicot reduces costs by moving manufacturing step

Uppsala, October 25, 2022. Dicot is moving parts of the manufacturing of its drug substance to lower costs and reduce transportations. It is the extraction process that is being moved to South Africa where the starting material is already handled and where the company has established collaboration partners.


Dicot har skickat in ny patentansökan

Nyhet: Uppsala, 17 oktober 2022. Dicot AB meddelar idag att bolaget har skickat in en ny patentansökan till Patent- och registreringsverket. Detta följer den IP-plan som tidigare kommunicerats av bolaget. Nya patent ger 20 års marknadsexklusivitet från det att en ansökan skickas in.


Dicot has submitted a new patent application

News: Uppsala, October 17, 2022. Dicot AB announces today that the company has submitted a new patent application to the Patent and Registration Office. This is according to the IP plan previously communicated by the company. New patents provide 20 years of market exclusivity from the time an application is submitted.


Dicot rapporterar goda resultat från prekliniska toxikologistudier

Dicot rapporterar att de prekliniska toxikologistudierna som nu genomförs, hittills visar att läkemedelskandidaten LIB-01 har en god säkerhetsprofil.


Dicot reports good results from preclinical toxicology studies

Dicot reports that the preclinical toxicology studies that are now being conducted, so far show that the drug candidate LIB-01 has a good safety profile.


EU-kommissionen har valt ut Dicot att tävla i Innovation Radar Prize

Uppsala, 7 september 2022. EU-kommissionen har utifrån tusentals små och medelstora europeiska företag valt ut Dicot som ett av bolagen att bjuda in till tävlingen Innovation Radar Prize 2022.


The European Commission has selected Dicot to compete in the Innovation Radar Prize

Uppsala, September 7, 2022. The European Commission has selected Dicot from thousands of small and medium-sized European companies as one of the companies to participate in the Innovation Radar Prize 2022.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted